Neumora Therapeutics, Inc. Common Stock

NASDAQ: NMRA · Healthcare · Biotechnology

PublicHQ Watertown, DECIK 0001885522Reports USD

#1 of 1,394 Healthcare companies by revenue

EA Score

——

FH 28DQ —GM —SS 48

v0.1 · 35/100 weight · pillars only

↑ market scale, filing timeliness · ↓ Piotroski F, listing tenure

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$236.9M

Employees

110

Market cap

$309.4M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$236.9M-$236.9M2025

Operating income-$241.2M-$241.2M2025

Total assets$191.0M$191.0M2025

Liabilities$87.2M$87.2M2025

Equity$103.9M$103.9M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Neumora Therapeutics, Inc. Common Stock earned -$236.9M in FY2025 net income.

Peers · Healthcare

Alpha Teknova, Inc.57C Carlsmed, Inc.43D Cartesian Therapeutics, Inc.40D Foghorn Therapeutics Inc.43D

Key facts

CEODaljit Singh Aurora

SectorHealthcare

IndustryBiotechnology

HeadquartersWatertown, DE

ExchangeNASDAQ: NMRA

Employees110

IPO date2023-09-15

Latest filings

8-K2026-06-15 8-K2026-05-29 10-Q2026-05-07 8-K2026-05-07 DEF 14A2026-04-17 8-K2026-03-30 10-K2026-03-30 8-K2026-02-11

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.